Welcome
Support Centre
11 October 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised double-blind placebo-controlled cancer prevention trial with an estimated duration of 5 years and with 52,000 subjects recruited from the general populations of the UK, Denmark, Sweden, Finland and the United States
ISRCTN ISRCTN64336220
ClinicalTrials.gov identifier
Public title A randomised double-blind placebo-controlled cancer prevention trial with an estimated duration of 5 years and with 52,000 subjects recruited from the general populations of the UK, Denmark, Sweden, Finland and the United States
Scientific title
Acronym N/A
Serial number at source PRECISE
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised double-blind placebo-controlled
Countries of recruitment Denmark, Finland, Sweden, UK, USA
Disease/condition/study domain Multiple cancer sites
Participants - inclusion criteria All those aged between 60 and 74 years are eligible.
Participants - exclusion criteria 1. Southwest Oncology Group (SWOG) performance status score of greater then 1 or equivalent
2. Active liver or kidney disease
3. Prior diagnosis of cancer
4. Diagnosed Human Immunodeficiency Virus (HIV) infection
5. Disminished mental capacity
6. Taking 50 micrograms/day or more of selenium supplements
Anticipated start date 01/01/1995
Anticipated end date 29/06/2001
Status of trial Completed
Patient information material
Target number of participants 52000
Interventions Four treatment groups:
1. Placebo
2. 100 micrograms selenium/day
3. 200 micrograms selenium/day
4. 300 micrograms selenium/day
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Cancer Research UK
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor Cancer Research UK (CRUK) (UK)
  Address PO Box 123
Lincoln's Inn Fields
  City/town London
  Zip/Postcode WC2A 3PX
  Country United Kingdom
  Tel +44 (0)20 7317 5186
  Fax +44 (0)20 7487 4302
  Email kate.law@cancer.org.uk
  Sponsor website: http://www.cancer.org.uk
Date applied 01/07/2001
Last edited 28/05/2008
Date ISRCTN assigned 01/07/2001
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central